ArticleJournal of market access & health policy2017

Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy.

Andrea Aiello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.